January 31, 2013
5 PM in Mainz, Germany
TRON – Building 708 at University Medical Center Mainz
Dr. Pierre van der Bruggen
Ludwig Institute for Cancer Research in Brussels
“Regulation of T lymphocyte function in tumors”
Van der Bruggen is group leader at de Duve Institute, Université catholique de Louvain, and Ludwig Institute for Cancer Research in Brussels. His research focuses on the identification of tumor antigens recognized by T cells and a mechanism causing anergy of CD8 and CD4 T lymphocytes. Van der Bruggen’s group tries to understand why tumor-infiltrating lymphocytes are unable to kill tumor cells, and to find strategies to overcome this blockage. The group has discovered a new type of anergy of human tumor-infiltrating lymphocytes, apparently due to the presence of galectin-3, a lectin abundant in tumors, as it is corrected by galectin ligands. They are further analyzing the mechanisms by which galectin ligands reverse the impaired function and are looking for agents that correct this function. They are further intending to set up clinical trials combining anti-tumoral therapeutic vaccination and injection of galectin ligands.